SCHEMBL16396285

SCHEMBL16396285

COC(=O)c1cc(Br)cc(OCC(F)(F)F)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.61
LMNA P02545 5/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PAX8 Q06710 2/20 0.44
AMD1 P17707 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.42
HTT P42858 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
GAA P10253 2/20 0.42
S1PR2 O95136 1/20 0.42
S1PR4 O95977 1/20 0.42
XBP1 P17861 1/20 0.42
S1PR3 Q99500 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10068542 0.89 NOTUM (0.49) NOTUMLMNAMEN1KMT2APAX8
SCHEMBL3578072 0.87 MEN1 (0.58) NOTUMLMNAMEN1KMT2APAX8
SCHEMBL19127993 0.86 NOTUM (0.55) NOTUMLMNASMN1; SMN2RAB9ANPC1
SCHEMBL17824254 0.85 NOTUM (0.50) NOTUMLMNARAB9ACYP1A2MAPT
SCHEMBL17824099 0.84 NOTUM (0.49) NOTUMLMNARAB9AMAPTKDM4E
SCHEMBL10068550 0.84 MEN1 (0.46) NOTUMLMNAMEN1KMT2APAX8
SCHEMBL16727035 0.84 NOTUM (0.44) NOTUMLMNAMEN1KMT2APAX8
SCHEMBL17703910 0.84 NOTUM (0.59) NOTUMLMNAMEN1KMT2APAX8
SCHEMBL2277550 0.83 L3MBTL1 (0.45) NOTUMLMNAMEN1KMT2APAX8
SCHEMBL16397245 0.83 NOTUM (0.53) NOTUMLMNAMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-08-29 US disclosed
EP-4301752-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2024-01-10 EP disclosed
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-01-09 US disclosed
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Apollo Therapeutics Limited (GB) 2023-08-10 US disclosed
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Apollo Therapeutics Limited (GB) 2023-08-10 US disclosed
WO-2022185041-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2022-09-09 WO disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 WO disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 NOTUM 3816/4885LMNA 1058/4885MEN1 4029/4885
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof ABCB11, CEL, NDC1 NOTUM 392/4885LMNA 438/4885MEN1 3798/4885
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 NOTUM 3816/4885LMNA 1058/4885MEN1 4029/4885
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB NOTUM 910/4885LMNA 1205/4885MEN1 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.